NCT03993912: Phase 3 - Lenalidomide & SC Daratumumab vs Lenalidomide and Dex in NDMM - (IFM2017_03)
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dex or Daratumumab, Bortezomib, & Dex in NDMM Myeloma
NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy
NCT04155749: Phase 1 : CART-ddBCMA - Master Protocol for Cell Therapies in Multiple Myeloma
NCT03933735: Phase 1: ABBV-383 (TNB-383B) in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03941860: Phase 3 - EAA171 - OPTIMUM - Addition of Ixazomib to Lenalidomide in Residual Myeloma
NCT04126200: Phase 1/2 - Belantamab Mafodotin as Monotherapy & With Anti-cancer Rx (RRMM) (DREAMM 5)
NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Plasmacytoma
NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM
Myeloma Canada: Multiple Myeloma Stem Cell Transplant
NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420
What is Multiple Myeloma? - Drs. Landgren and Gertz HealthTree University Myeloma
NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed Myeloma
NCT03798678: Phase 1 - CB-839 HCl + Carfilzomib and Dex - Refractory MM
NCT03848845: Phase 1/2: GSK2857916 in Combination With Pembrolizumab in RRMM Myeloma- DREAMM 4
How Long Will I Live with Multiple Myeloma and is There a Cure? HealthTree University Myeloma
NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population
NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM
NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM - MMY3019 CEPHEUS
NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab
NCT03549442: Phase 1 - CART-BCMA +/- huCART19 as Consolidation High Risk MM
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)